Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, et al. (August 2006). "A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators". Molecular Pharmacology. 70 (2): 616–626. doi:10.1124/mol.105.021857. PMID16645124. S2CID2719603.
Lavreysen H, Wouters R, Bischoff F, Nóbrega Pereira S, Langlois X, Blokland S, et al. (December 2004). "JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist". Neuropharmacology. 47 (7): 961–972. doi:10.1016/j.neuropharm.2004.08.007. PMID15555631. S2CID601322.
Lavreysen H, Janssen C, Bischoff F, Langlois X, Leysen JE, Lesage AS (May 2003). "[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists". Molecular Pharmacology. 63 (5): 1082–1093. doi:10.1124/mol.63.5.1082. PMID12695537.
Kohara A, Takahashi M, Yatsugi S, Tamura S, Shitaka Y, Hayashibe S, et al. (January 2008). "Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models". Brain Research. 1191: 168–179. doi:10.1016/j.brainres.2007.11.035. PMID18164695. S2CID3236484.
Kohara A, Nagakura Y, Kiso T, Toya T, Watabiki T, Tamura S, et al. (September 2007). "Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models". European Journal of Pharmacology. 571 (1): 8–16. doi:10.1016/j.ejphar.2007.05.030. PMID17597604.
Kohara A, Toya T, Tamura S, Watabiki T, Nagakura Y, Shitaka Y, et al. (October 2005). "Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1". The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 163–169. doi:10.1124/jpet.105.087171. PMID15976016. S2CID15291494.
Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, et al. (June 2007). "Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC)". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1144–1153. doi:10.1124/jpet.106.116574. PMID17360958. S2CID10065500.
Lemieszek MK, Stepulak A, Sawa-Wejksza K, Czerwonka A, Ikonomidou C, Rzeski W (2018). "Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins". Anti-Cancer Agents in Medicinal Chemistry. 18 (4): 565–572. doi:10.2174/1871520618666180228152713. PMID29493465. S2CID3605151.
Nagasawa K, Aoki H, Yasuda E, Nagai K, Shimohama S, Fujimoto S (July 2004). "Possible involvement of group I mGluRs in neuroprotective effect of theanine". Biochemical and Biophysical Research Communications. 320 (1): 116–122. doi:10.1016/j.bbrc.2004.05.143. PMID15207710.
Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, et al. (August 2006). "A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators". Molecular Pharmacology. 70 (2): 616–626. doi:10.1124/mol.105.021857. PMID16645124. S2CID2719603.
Lavreysen H, Wouters R, Bischoff F, Nóbrega Pereira S, Langlois X, Blokland S, et al. (December 2004). "JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist". Neuropharmacology. 47 (7): 961–972. doi:10.1016/j.neuropharm.2004.08.007. PMID15555631. S2CID601322.
Lavreysen H, Janssen C, Bischoff F, Langlois X, Leysen JE, Lesage AS (May 2003). "[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists". Molecular Pharmacology. 63 (5): 1082–1093. doi:10.1124/mol.63.5.1082. PMID12695537.
Kohara A, Takahashi M, Yatsugi S, Tamura S, Shitaka Y, Hayashibe S, et al. (January 2008). "Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models". Brain Research. 1191: 168–179. doi:10.1016/j.brainres.2007.11.035. PMID18164695. S2CID3236484.
Kohara A, Nagakura Y, Kiso T, Toya T, Watabiki T, Tamura S, et al. (September 2007). "Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models". European Journal of Pharmacology. 571 (1): 8–16. doi:10.1016/j.ejphar.2007.05.030. PMID17597604.
Kohara A, Toya T, Tamura S, Watabiki T, Nagakura Y, Shitaka Y, et al. (October 2005). "Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1". The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 163–169. doi:10.1124/jpet.105.087171. PMID15976016. S2CID15291494.
Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, et al. (June 2007). "Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC)". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1144–1153. doi:10.1124/jpet.106.116574. PMID17360958. S2CID10065500.
Lemieszek MK, Stepulak A, Sawa-Wejksza K, Czerwonka A, Ikonomidou C, Rzeski W (2018). "Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins". Anti-Cancer Agents in Medicinal Chemistry. 18 (4): 565–572. doi:10.2174/1871520618666180228152713. PMID29493465. S2CID3605151.
Nagasawa K, Aoki H, Yasuda E, Nagai K, Shimohama S, Fujimoto S (July 2004). "Possible involvement of group I mGluRs in neuroprotective effect of theanine". Biochemical and Biophysical Research Communications. 320 (1): 116–122. doi:10.1016/j.bbrc.2004.05.143. PMID15207710.
ncbi.nlm.nih.gov
"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, et al. (August 2006). "A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators". Molecular Pharmacology. 70 (2): 616–626. doi:10.1124/mol.105.021857. PMID16645124. S2CID2719603.
Lavreysen H, Wouters R, Bischoff F, Nóbrega Pereira S, Langlois X, Blokland S, et al. (December 2004). "JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist". Neuropharmacology. 47 (7): 961–972. doi:10.1016/j.neuropharm.2004.08.007. PMID15555631. S2CID601322.
Kohara A, Takahashi M, Yatsugi S, Tamura S, Shitaka Y, Hayashibe S, et al. (January 2008). "Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models". Brain Research. 1191: 168–179. doi:10.1016/j.brainres.2007.11.035. PMID18164695. S2CID3236484.
Kohara A, Toya T, Tamura S, Watabiki T, Nagakura Y, Shitaka Y, et al. (October 2005). "Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1". The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 163–169. doi:10.1124/jpet.105.087171. PMID15976016. S2CID15291494.
Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, et al. (June 2007). "Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC)". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1144–1153. doi:10.1124/jpet.106.116574. PMID17360958. S2CID10065500.
Lemieszek MK, Stepulak A, Sawa-Wejksza K, Czerwonka A, Ikonomidou C, Rzeski W (2018). "Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins". Anti-Cancer Agents in Medicinal Chemistry. 18 (4): 565–572. doi:10.2174/1871520618666180228152713. PMID29493465. S2CID3605151.
